News & Events

NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014

NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014

Aberdeen, UK – 20 June 2014 – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that Dr. Deborah O’Neil, the Company’s Chief Executive Officer, was named an EY Scotland Entrepreneur of the Year 2014 at the awards dinner held at The Gleneagles Hotel in Perthshire, Scotland last night.

Deborah was amongst 19 other business leaders whose achievements were also recognised and with whom she will compete for the title of UK Entrepreneur of the Year, which will be awarded this October at a ceremony in London, UK. UK finals winner will join the other global country winners in Monte Carlo in 2015 to vie for the title of World Entrepreneur of the Year.

Dr Deborah O’Neil, CEO of NovaBiotics, said: “It was a wonderful surprise to receive this award and I would like to thank our employees and stakeholders who have supported NovaBiotics, working tirelessly on innovative solutions that will make a difference in patients’ lives and address a looming global anti-infectives crisis. To be recognised amongst some of the most successful business leaders in our region is a great honour and highlights the expertise and hard work of everyone over the past ten years.”

Jim Bishop, Senior Partner and Entrepreneur of the Year Leader at EY Scotland, said: "Dr O'Neil is a true entrepreneur; an exceptional person who had the courage to risk everything in pursuit of her vision."

The EY Entrepreneur of the Year™ programme is considered the world's most prestigious business award and is held in more than 145 cities and in more than 60 countries worldwide.  The Award identifies and celebrates the achievements of the world’s most successful, growing and dynamic businesses, taking into consideration entrepreneurial spirit, innovation, strategic direction, financial performance, national and global impact, and approach to social responsibility.

Notes To Editors

About NovaBiotics

NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.  A leading innovator in the anti-infectives space, the Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections.

Further information is available at


Issued for and on behalf of NovaBiotics by Instinctif Partners.

To contact the NovaBiotics team at Instinctif Partners, email


back to news


Melanie Toyne-SewellManaging Partner